Sartorius Stedim Biotech SA
DIM
Company Profile
Business description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact
Otto-Brenner-Strasse 20
Goettingen37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
10,456
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.80 | 67.50 | 0.77% |
| CAC 40 | 8,203.43 | 4.14 | 0.05% |
| DAX 40 | 24,433.06 | 183.16 | -0.74% |
| Dow JONES (US) | 50,872.11 | 86.10 | 0.17% |
| FTSE 100 | 10,227.33 | 145.87 | -1.41% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 25,678.82 | 250.84 | -0.97% |
| Nikkei 225 | 65,416.63 | 1,392.03 | 2.17% |
| NZX 50 Index | 13,163.19 | 40.89 | -0.31% |
| S&P 500 | 7,386.65 | 19.08 | -0.26% |
| S&P/ASX 200 | 8,604.20 | 70.70 | 0.83% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |